319 related articles for article (PubMed ID: 26134396)
1. A lipid switch unlocks Parkinson's disease-associated ATP13A2.
Holemans T; Sørensen DM; van Veen S; Martin S; Hermans D; Kemmer GC; Van den Haute C; Baekelandt V; Günther Pomorski T; Agostinis P; Wuytack F; Palmgren M; Eggermont J; Vangheluwe P
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):9040-5. PubMed ID: 26134396
[TBL] [Abstract][Full Text] [Related]
2. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.
Demirsoy S; Martin S; Motamedi S; van Veen S; Holemans T; Van den Haute C; Jordanova A; Baekelandt V; Vangheluwe P; Agostinis P
Hum Mol Genet; 2017 May; 26(9):1656-1669. PubMed ID: 28334751
[TBL] [Abstract][Full Text] [Related]
3. Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2.
Martin S; van Veen S; Holemans T; Demirsoy S; van den Haute C; Baekelandt V; Agostinis P; Eggermont J; Vangheluwe P
Parkinsons Dis; 2016; 2016():9531917. PubMed ID: 27073711
[TBL] [Abstract][Full Text] [Related]
4. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H
Fujii T; Nagamori S; Wiriyasermkul P; Zheng S; Yago A; Shimizu T; Tabuchi Y; Okumura T; Fujii T; Takeshima H; Sakai H
Nat Commun; 2023 Apr; 14(1):2174. PubMed ID: 37080960
[TBL] [Abstract][Full Text] [Related]
6. The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity.
Rinaldi DE; Corradi GR; Cuesta LM; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta; 2015 Aug; 1848(8):1646-55. PubMed ID: 25912790
[TBL] [Abstract][Full Text] [Related]
7. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
Park JS; Blair NF; Sue CM
Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
9. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
[TBL] [Abstract][Full Text] [Related]
10. ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion.
Wang R; Tan J; Chen T; Han H; Tian R; Tan Y; Wu Y; Cui J; Chen F; Li J; Lv L; Guan X; Shang S; Lu J; Zhang Z
J Cell Biol; 2019 Jan; 218(1):267-284. PubMed ID: 30538141
[TBL] [Abstract][Full Text] [Related]
11. ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress.
Vrijsen S; Besora-Casals L; van Veen S; Zielich J; Van den Haute C; Hamouda NN; Fischer C; Ghesquière B; Tournev I; Agostinis P; Baekelandt V; Eggermont J; Lambie E; Martin S; Vangheluwe P
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31198-31207. PubMed ID: 33229544
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal defects in ATP13A2 and GBA associated familial Parkinson's disease.
Sato S; Li Y; Hattori N
J Neural Transm (Vienna); 2017 Nov; 124(11):1395-1400. PubMed ID: 28894968
[TBL] [Abstract][Full Text] [Related]
13. ATP13A2 Declines Zinc-Induced Accumulation of α-Synuclein in a Parkinson's Disease Model.
Gao H; Sun H; Yan N; Zhao P; Xu H; Zheng W; Zhang X; Wang T; Guo C; Zhong M
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887392
[TBL] [Abstract][Full Text] [Related]
14. ATP13A2 Regulates Cellular α-Synuclein Multimerization, Membrane Association, and Externalization.
Si J; Van den Haute C; Lobbestael E; Martin S; van Veen S; Vangheluwe P; Baekelandt V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799982
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes.
Kong SM; Chan BK; Park JS; Hill KJ; Aitken JB; Cottle L; Farghaian H; Cole AR; Lay PA; Sue CM; Cooper AA
Hum Mol Genet; 2014 Jun; 23(11):2816-33. PubMed ID: 24603074
[TBL] [Abstract][Full Text] [Related]
16. ATP13A2 deficiency disrupts lysosomal polyamine export.
van Veen S; Martin S; Van den Haute C; Benoy V; Lyons J; Vanhoutte R; Kahler JP; Decuypere JP; Gelders G; Lambie E; Zielich J; Swinnen JV; Annaert W; Agostinis P; Ghesquière B; Verhelst S; Baekelandt V; Eggermont J; Vangheluwe P
Nature; 2020 Feb; 578(7795):419-424. PubMed ID: 31996848
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
[TBL] [Abstract][Full Text] [Related]
18. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R
Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957
[TBL] [Abstract][Full Text] [Related]
19. The strategic function of the P5-ATPase ATP13A2 in toxic waste disposal.
de Tezanos Pinto F; Adamo HP
Neurochem Int; 2018 Jan; 112():108-113. PubMed ID: 29169913
[TBL] [Abstract][Full Text] [Related]
20. Parkinson disease related ATP13A2 evolved early in animal evolution.
Sørensen DM; Holemans T; van Veen S; Martin S; Arslan T; Haagendahl IW; Holen HW; Hamouda NN; Eggermont J; Palmgren M; Vangheluwe P
PLoS One; 2018; 13(3):e0193228. PubMed ID: 29505581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
